ResMed is selling its post-acute care EHR business, MatrixCare, to private equity firm Frazier Healthcare Partners for $490 million. The move lets the respiratory device maker redirect capital toward faster-growing sleep and breathing health products and its digital health ecosystem. The deal is expected to close in Q1 of ResMed's fiscal 2027.
ResMed is trimming its portfolio with a $490 million sale of MatrixCare — its electronic health record software platform for post-acute care — to private equity firm Frazier Healthcare Partners. The deal, announced Tuesday, is designed to help ResMed sharpen its focus on its core sleep and breathing health devices and expand its connected, home-based care offerings.
MatrixCare, which ResMed originally acquired for $750 million in 2018, serves more than 15,000 healthcare providers across skilled nursing, senior living, and long-term care settings. Analysts at KeyBanc noted that MatrixCare's revenue growth had lagged company averages, and shedding the unit should accelerate growth in ResMed's remaining software business. The transaction is expected to close in Q1 of ResMed's fiscal 2027 (ending September).
By the Numbers:
Why it matters: This divestiture signals a broader strategic pivot at ResMed toward higher-growth digital health and device segments, while MatrixCare's move to private equity could reshape how post-acute care providers access and invest in EHR technology.
